Albumin reprograms the B cell transcriptional landscape and improves neutrophil antimicrobial function in patients with decompensated cirrhosis
Joan Clària,
Ferran Aguilar,
Juan-José Lozano,
Laura Jiménez-Gracia,
Juan C. Nieto,
Berta Romero-Grimaldo,
Xavi Marcos-Fa,
Emma Giarracco,
Emmanuel Weiss,
Jonel Trebicka,
Inmaculada Hernàndez,
Javier Fernandez,
Mireia Casulleras,
Cristina López-Vicario,
Sinan Muldur,
Alex Hopke,
Alexandru Vlagea,
Ana M. Aransay,
Domenica Marchese,
Mauro Bernardi,
Rajiv Jalan,
Paolo Angeli,
Giuliana Magri,
Andrea Cerutti,
Daniel Irimia,
Holger Heyn,
Vicente Arroyo,
Richard Moreau
Affiliations
Joan Clària
European Foundation for the Study of Chronic Liver Failure (EF CLIF), European Association for the Study of the Liver (EASL)–CLIF Consortium, and Grifols Chair, Barcelona, Spain; Hospital Clínic-IDIBAPS, Barcelona, Spain; CIBER of Hepatic and Digestive Diseases (CIBERehd); Barcelona, Spain; Universitat de Barcelona, Barcelona, Spain; Corresponding authors. Address: EF CLIF, Travessera de Gràcia 11, 7th Floor, 08021, Barcelona, Spain.
Ferran Aguilar
European Foundation for the Study of Chronic Liver Failure (EF CLIF), European Association for the Study of the Liver (EASL)–CLIF Consortium, and Grifols Chair, Barcelona, Spain
Juan-José Lozano
CIBER of Hepatic and Digestive Diseases (CIBERehd); Barcelona, Spain
Laura Jiménez-Gracia
Universitat de Barcelona, Barcelona, Spain; Centre Nacional d’Anàlisi Genòmica (CNAG), Barcelona, Spain
Juan C. Nieto
Universitat de Barcelona, Barcelona, Spain; Centre Nacional d’Anàlisi Genòmica (CNAG), Barcelona, Spain
Berta Romero-Grimaldo
European Foundation for the Study of Chronic Liver Failure (EF CLIF), European Association for the Study of the Liver (EASL)–CLIF Consortium, and Grifols Chair, Barcelona, Spain; Hospital Clínic-IDIBAPS, Barcelona, Spain; CIBER of Hepatic and Digestive Diseases (CIBERehd); Barcelona, Spain
Xavi Marcos-Fa
Translational Clinical Research Program, Institute “Hospital del Mar” for Medical Investigations (IMIM), Barcelona, Spain
Emma Giarracco
Translational Clinical Research Program, Institute “Hospital del Mar” for Medical Investigations (IMIM), Barcelona, Spain
Emmanuel Weiss
European Foundation for the Study of Chronic Liver Failure (EF CLIF), European Association for the Study of the Liver (EASL)–CLIF Consortium, and Grifols Chair, Barcelona, Spain; Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Cité, Centre de Recherche sur l’Inflammation (CRI), Paris, France; Assistance Publique–Hôpitaux de Paris (AP-HP), Hôpital Beaujon, Département d’Anesthésie et de Réanimation, DMU Parabol, Clichy, France
Jonel Trebicka
European Foundation for the Study of Chronic Liver Failure (EF CLIF), European Association for the Study of the Liver (EASL)–CLIF Consortium, and Grifols Chair, Barcelona, Spain; Department of Internal Medicine B, University of Münster, Münster, Germany
Inmaculada Hernàndez
Universitat de Barcelona, Barcelona, Spain; Centre Nacional d’Anàlisi Genòmica (CNAG), Barcelona, Spain; Institute for Research in Biomedicine (IRB), Barcelona, Spain
Javier Fernandez
European Foundation for the Study of Chronic Liver Failure (EF CLIF), European Association for the Study of the Liver (EASL)–CLIF Consortium, and Grifols Chair, Barcelona, Spain; Hospital Clínic-IDIBAPS, Barcelona, Spain
Mireia Casulleras
European Foundation for the Study of Chronic Liver Failure (EF CLIF), European Association for the Study of the Liver (EASL)–CLIF Consortium, and Grifols Chair, Barcelona, Spain; Hospital Clínic-IDIBAPS, Barcelona, Spain
Cristina López-Vicario
European Foundation for the Study of Chronic Liver Failure (EF CLIF), European Association for the Study of the Liver (EASL)–CLIF Consortium, and Grifols Chair, Barcelona, Spain; Hospital Clínic-IDIBAPS, Barcelona, Spain; CIBER of Hepatic and Digestive Diseases (CIBERehd); Barcelona, Spain
Sinan Muldur
Center for Engineering in Medicine and Surgery, Massachusetts General Hospital, Shriners Burns Hospital, Harvard Medical School, Boston, MA, USA
Alex Hopke
Center for Engineering in Medicine and Surgery, Massachusetts General Hospital, Shriners Burns Hospital, Harvard Medical School, Boston, MA, USA
Alexandru Vlagea
Hospital Clínic-IDIBAPS, Barcelona, Spain
Ana M. Aransay
CIBER of Hepatic and Digestive Diseases (CIBERehd); Barcelona, Spain; Center for Cooperative Research in Biosciences (CIC bioGUNE), Parque Tecnológico de Bizkaia, Derio, Spain
Domenica Marchese
Universitat de Barcelona, Barcelona, Spain; Centre Nacional d’Anàlisi Genòmica (CNAG), Barcelona, Spain
Mauro Bernardi
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
Rajiv Jalan
European Foundation for the Study of Chronic Liver Failure (EF CLIF), European Association for the Study of the Liver (EASL)–CLIF Consortium, and Grifols Chair, Barcelona, Spain; Liver Failure Group, Institute for Liver Disease Health, University College London, Royal Free Hospital, London, UK
Paolo Angeli
European Foundation for the Study of Chronic Liver Failure (EF CLIF), European Association for the Study of the Liver (EASL)–CLIF Consortium, and Grifols Chair, Barcelona, Spain; Unit of Internal Medicine and Hepatology (UIMH), Department of Medicine – DIMED, University of Padova, Padova, Italy
Giuliana Magri
Immunology Unit, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain
Andrea Cerutti
Translational Clinical Research Program, Institute “Hospital del Mar” for Medical Investigations (IMIM), Barcelona, Spain; Catalan Institute for Research and Advanced Studies (ICREA); Barcelona, Spain
Daniel Irimia
Center for Engineering in Medicine and Surgery, Massachusetts General Hospital, Shriners Burns Hospital, Harvard Medical School, Boston, MA, USA
Holger Heyn
Universitat de Barcelona, Barcelona, Spain; Centre Nacional d’Anàlisi Genòmica (CNAG), Barcelona, Spain
Vicente Arroyo
European Foundation for the Study of Chronic Liver Failure (EF CLIF), European Association for the Study of the Liver (EASL)–CLIF Consortium, and Grifols Chair, Barcelona, Spain
Richard Moreau
European Foundation for the Study of Chronic Liver Failure (EF CLIF), European Association for the Study of the Liver (EASL)–CLIF Consortium, and Grifols Chair, Barcelona, Spain; Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Cité, Centre de Recherche sur l’Inflammation (CRI), Paris, France; Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Beaujon, Service d’Hépatologie, Clichy, France; Corresponding authors. Address: EF CLIF, Travessera de Gràcia 11, 7th Floor, 08021, Barcelona, Spain.
Background & Aims: Patients with acutely decompensated (AD) cirrhosis are immunocompromised and particularly susceptible to infections. This study investigated the immunomodulatory actions of albumin by which this protein may lower the incidence of infections. Methods: Blood immunophenotyping was performed in 11 patients with AD cirrhosis and 10 healthy volunteers (HV). Bulk and single-cell RNA sequencing (scRNA-seq) and flow cytometry were performed in peripheral blood mononuclear cells (PBMCs) from 20 patients with AD cirrhosis and 34 HV exposed to albumin. Albumin’s effects on degranulation, phagocytosis, chemotaxis, and swarming of neutrophils from six patients with AD cirrhosis and nine HV were assessed by measuring myeloperoxidase enzymatic activity, the engulfment of fluorescent-labeled Escherichia coli and zymosan, and interactions of neutrophils with Candida albicans at single-cell resolution in microfluidic chambers, respectively. Whole blood RNA sequencing (RNA-seq) analyses were performed in 49 patients admitted for severe AD cirrhosis, of whom 30 received albumin during hospitalization. Results: Compared with HV, patients with AD cirrhosis showed severe lymphopenia and defective neutrophil antimicrobial function. Bulk and scRNA-seq analyses revealed significantly (false discovery rate [FDR] <0.05) increased signatures related to B cells, myeloid cells, and CD4+ T cells in PBMCs incubated with albumin. Changes in the B cell population were confirmed by flow cytometry. Neutrophils exposed to albumin also exhibited augmented chemotactic and degranulation responses, enhanced phagocytosis, and increased pathogen-restrictive swarming. RNA-seq data analysis in patients who had received albumin revealed specific upregulation of signatures related to B cells and neutrophils together with transcriptional changes in CD4+ T cells (FDR <0.05). Conclusions: The finding that albumin promotes the transcriptional reprogramming and expansion of the B cell compartment and improves neutrophil antimicrobial functions indicates mechanisms that may lower the incidence of infections in patients with severe AD cirrhosis receiving albumin therapy. Impact and implications:: Patients with acutely decompensated cirrhosis receiving albumin as treatment have a lower incidence of infections. The reason for this protection is currently unknown, but the present study provides data that support the ability of albumin to boost the antimicrobial functions of immune cells in these patients. Moreover, these findings encourage the design of controlled clinical studies specifically aimed at investigating the effects of albumin administration on the immune system.